E
Enterome
Microbiome decoded, healthcare transformed
Paris, France
35+
About Enterome
Industry:
Microbiome Drug Discovery
Founded:
2012
Founders:
Pierre Belichard
Status:
Private
Funding & Growth
Total Raised:
€155M+
Stage:
Series D
Key Investors:
Seventure Partners
Omnes Capital
Lundbeckfond Ventures
Danone
✓ Pros
- • Deep metagenomics + biocomputational platform
- • Well-funded (€155M+ raised)
- • Clinical-stage pipeline (multiple Phase 2 trials)
- • Novel microbiome-immunology science
✗ Cons
- • Small team (~36 people)
- • Clinical / biotech risk
- • Blends wet-lab with computational work (not pure dry-lab)
🧬 Bioinformatics Focus
Enterome is a clinical-stage biotech whose drug discovery runs on computational biology: its Mimicry platform mines a proprietary database of 20+ million full-length gut-microbiome proteins with biocomputational tools and bioassays to find molecular mimics of tumor antigens, feeding an off-the-shelf immunotherapy pipeline (glioblastoma, lymphoma, colorectal).
Founded in Paris in 2012 out of INRA's metagenomics platform.